• Earlier in 2026, Globus Medical reported first‑quarter results that exceeded consensus expectations for adjusted earnings per share and revenue, despite ongoing inflation, interest rate uncertainty, and foreign currency pressures that increased costs and added volatility.
• The company’s foreign currency transaction loss underscored the sensitivity of its internationally driven growth to exchange rate movements, even as investors reacted positively to the stronger‑than‑expected operating performance.
• Now, we’ll examine how this earnings beat, achieved amid inflation and currency headwinds, may influence Globus Medical’s broader investment narrative.

AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Globus Medical Investment Narrative Recap

To own Globus Medical, you need to believe in the long term demand for musculoskeletal devices and enabling technologies like robotics, while accepting meaningful execution and integration risk from NuVasive and Nevro. The Q1 2026 earnings beat supports the near term profit story, but it does not remove the key short term risk around currency exposure and international momentum, where foreign exchange volatility and supply chain complexity can still pressure margins.

Among recent developments, the reaffirmation of full year 2026 revenue guidance to US$3.18–3.22 billion is most relevant here, because it anchors expectations after a stronger first quarter. It suggests management is balancing the upside from better than expected results with the ongoing pressures from inflation, foreign exchange swings and integration costs, which remain central to how quickly any earnings upside can be converted into more durable value for shareholders.

Yet, behind the strong quarter, investors should still be alert to how foreign currency and international integration risks could...

Globus Medical's narrative projects $3.7 billion revenue and $649.0 million earnings by 2029. This requires 5.8% yearly revenue growth and about a $62 million earnings increase from $586.7 million today.

Uncover how Globus Medical's forecasts yield a $110.00 fair value, a 39% upside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming about US$3.4 billion in revenue by 2028 and modest margin gains, which is much more pessimistic than the base case and may look different once this strong quarter and currency volatility are fully reflected.

Explore 6 other fair value estimates on Globus Medical - why the stock might be worth 9% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Globus Medical research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Globus Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globus Medical's overall financial health at a glance.

Interested In Other Possibilities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.